BeaconEquity.com: Elite Pharmaceuticals (ELTP) Allergy Product Launch Triggers 30% Gains
Shares of Elite Pharmaceuticals Inc., a specialty pharmaceutical company, soared in yesterday's trading after the company, along with ECR Pharmaceuticals, announced the launch of Lodrane D®, an immediate release formulation of brompheniramine maleate and pseudophedrine HCI. The product will be manufactured by Elite, and promoted and distributed by ECR in the U.S. It will be available over-the-counter. Elite will be entitled to revenues for the manufacturing, packaging and laboratory study services of the product, as well as royalties on sales. With the U.S. allergy market currently estimated at $3.5 billion, the product has huge potential. Jerry Treppel, chairman and CEO…